RxDoctor Payments Data

Traci Bourgeois, MD

Family Medicine · Gulf Breeze, FLNPI 1922502772

Payments from drug & device makers

$407in general payments, 2019–2025

Across 20 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$137
  • AbbVie$54
  • Otsuka America Pharmaceutical, Inc.$37
  • Novartis$28
  • Exact Sciences$28
  • GSK$23
  • plus $99 from 6 others

What the payments were for

  • Food & beverage$407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$9,389
Medicare patients
42
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$107,041
JardianceEmpagliflozin74$80,291
LinzessLinaclotide65$36,602
MounjaroTirzepatide22$27,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,755
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$15,571
TrulicityDulaglutide11$12,734
MovantikNaloxegol Oxalate13$6,137
FarxigaDapagliflozin Propanediol12$5,981
BrilintaTicagrelor12$5,592
Novolog FlexpenInsulin Aspart14$4,943
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,029
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,593
Gabapentin186$2,589
Sucralfate17$1,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$137$107,04188 claims
AbbVieLinzess$54$36,60265 claims
GSKTrelegy Ellipta$23$15,75515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Gulf Breeze

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →